J.-L. Canon

865 total citations
22 papers, 685 citations indexed

About

J.-L. Canon is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J.-L. Canon has authored 22 papers receiving a total of 685 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 6 papers in Surgery and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J.-L. Canon's work include Lung Cancer Research Studies (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Cancer Treatment and Pharmacology (4 papers). J.-L. Canon is often cited by papers focused on Lung Cancer Research Studies (7 papers), Colorectal Cancer Treatments and Studies (6 papers) and Cancer Treatment and Pharmacology (4 papers). J.-L. Canon collaborates with scholars based in Belgium, Australia and United Kingdom. J.-L. Canon's co-authors include Marc Peeters, Fernando Rivera, Eric Van Cutsem, M. Michael, Scott Berry, David Cunningham, John Bridgewater, M. Mazier, Vassilis Georgoulias and Albrecht Kretzschmar and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

J.-L. Canon

21 papers receiving 667 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J.-L. Canon Belgium	11	486	197	177	106	93	22	685
Andrea Mancuso Italy	14	432 0.9×	299 1.5×	74 0.4×	82 0.8×	202 2.2×	35	726
Patrizia Trenta Italy	11	314 0.6×	229 1.2×	146 0.8×	98 0.9×	143 1.5×	21	535
Jean‐Nicolas Munck France	12	214 0.4×	70 0.4×	84 0.5×	76 0.7×	71 0.8×	21	413
Xiaowei Dang China	12	224 0.5×	165 0.8×	95 0.5×	92 0.9×	163 1.8×	33	509
K. W. Jauch Germany	5	217 0.4×	66 0.3×	58 0.3×	171 1.6×	82 0.9×	9	518
Yvonne Lassere United States	14	761 1.6×	320 1.6×	69 0.4×	205 1.9×	146 1.6×	20	887
Beata Herberger Austria	13	516 1.1×	224 1.1×	398 2.2×	337 3.2×	119 1.3×	19	810
Atsushi Takeshita Japan	13	279 0.6×	140 0.7×	184 1.0×	154 1.5×	103 1.1×	40	580
Aya Nakaya Japan	13	290 0.6×	131 0.7×	39 0.2×	38 0.4×	102 1.1×	54	601
D. P. Ryan United States	13	241 0.5×	180 0.9×	34 0.2×	108 1.0×	94 1.0×	31	510

Countries citing papers authored by J.-L. Canon

Since Specialization

Citations

This map shows the geographic impact of J.-L. Canon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.-L. Canon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.-L. Canon more than expected).

Fields of papers citing papers by J.-L. Canon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.-L. Canon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.-L. Canon. The network helps show where J.-L. Canon may publish in the future.

Co-authorship network of co-authors of J.-L. Canon

This figure shows the co-authorship network connecting the top 25 collaborators of J.-L. Canon. A scholar is included among the top collaborators of J.-L. Canon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.-L. Canon. J.-L. Canon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Hendlisz, Alain, Sandrine Aspeslagh, Michaël Vouche, et al.. (2018). Phase I studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic colorectal cancer. Annals of Oncology. 29. viii203–viii203. 1 indexed citations

2.

Rivera, Fernando, Meinolf Karthaus, J. Randolph Hecht, et al.. (2015). 2014 Final analysis of the PEAK trial: Overall survival (OS) and tumour responses during first-line treatment with mFOLFOX6 + either panitumumab (pmab) or bevacizumab (bev) in patients (pts) with metastatic colorectal carcinoma (mCRC). European Journal of Cancer. 51. S332–S333. 3 indexed citations

3.

Béguin, Yves, et al.. (2010). High prevalence of anaemia and limited use of therapy in cancer patients: a Belgian survey (Anaemia Day 2008). Supportive Care in Cancer. 20(1). 23–28. 15 indexed citations

4.

Medioni, J., Joseph Kerger, J.-L. Canon, et al.. (2009). A phase I study of sorafenib in association with docetaxel-prednisone in chemonaive metastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 27(15_suppl). 5153–5153. 1 indexed citations

5.

Cutsem, Eric Van, Fernando Rivera, Scott Berry, et al.. (2009). Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Annals of Oncology. 20(11). 1842–1847. 423 indexed citations

6.

Detrait, Marie Y., Lionel D’Hondt, M. André, et al.. (2008). Agrobacterium radiobacter bacteremia in oncologic and geriatric patients: presentation of two cases and review of the literature. International Journal of Infectious Diseases. 12(6). e7–e10. 15 indexed citations

7.

D’Hondt, Lionel, et al.. (2007). Ovarian cancer associated with carcinomatous meningitis: a case report and review of the literature. International Journal of Gynecological Cancer. 17(5). 1136–1140. 3 indexed citations

8.

Machiels, J-P., Christine Sempoux, Pierre Scalliet, et al.. (2006). Phase I study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Journal of Clinical Oncology. 24(18_suppl). 3552–3552. 5 indexed citations

9.

Kotasek, Dusan, J.-L. Canon, Jesús F. San Miguel, et al.. (2004). Correction/Maintenance Dosing (Front Loading) of Darbepoetin alfa: Final Results from a Randomized Phase 3 Active Controlled Trial.. Blood. 104(11). 1636–1636. 14 indexed citations

10.

Duck, Lionel, Christine Sempoux, Brigitte Honhon, et al.. (2004). A phase II study of preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with locally advanced rectal adenocarcinoma. Journal of Clinical Oncology. 22(14_suppl). 3552–3552. 10 indexed citations

11.

Duck, Lionel, Christine Sempoux, Brigitte Honhon, et al.. (2004). A phase II study of preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with locally advanced rectal adenocarcinoma. Journal of Clinical Oncology. 22(14_suppl). 3552–3552. 3 indexed citations

12.

Johnsen, Hans Erik, J.-L. Canon, Thierry Guillaume, et al.. (2000). Highly purified CD34+ cells isolated using magnetically activated cell selection provide rapid engraftment following high-dose chemotherapy in breast cancer patients. Bone Marrow Transplantation. 25(3). 243–249. 31 indexed citations

13.

Velde, Helgi van de, Jean-François Rosier, Yves Humblet, et al.. (1999). Moderate dose-escalation of combination chemotherapy with concomitant thoracic radiotherapy in limited-disease small-cell lung cancer: Prolonged intrathoracic tumor control and high central nervous system relapse rate. Annals of Oncology. 10(9). 1051–1058. 10 indexed citations

14.

Froment, Olivier, et al.. (1998). BRCA1 and BRCA2 mutations in Belgian families with a history of breast and/or ovarian cancer. European Journal of Cancer Prevention. 7. S3–S6. 33 indexed citations

15.

Weynants, P., Leon Bosquée, J.-L. Canon, et al.. (1997). 95 Concomitant high-dose chemotherapy (HDCt) and radiotherapy (Rt) with G-CSF and peripheral blood stem cell (PBSC) rescue for limited (LD) small cell lung cancer (SCLC). Lung Cancer. 18. 27–27. 1 indexed citations

16.

Bleiberg, Harry, et al.. (1995). Optimal combination therapy with Navoban® (tropisetron) in patients with incomplete control of chemotherapy-induced nausea and vomiting. Anti-Cancer Drugs. 6. 22–30. 3 indexed citations

17.

Hulstaert, Frank, Simon Van Belle, Harry Bleiberg, et al.. (1994). Optimal combination therapy with tropisetron in 445 patients with incomplete control of chemotherapy-induced nausea and vomiting.. Journal of Clinical Oncology. 12(11). 2439–2446. 20 indexed citations

18.

D’Hondt, Véronique, P. Weynants, Yves Humblet, et al.. (1993). Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: a placebo-controlled randomized phase Ib study.. Journal of Clinical Oncology. 11(11). 2063–2071. 48 indexed citations

19.

Weynants, P., Yves Humblet, J.-L. Canon, & Michel Symann. (1991). Biology of small cell lung cancer: An overview. Lung Cancer. 7(3). 211–211. 22 indexed citations

20.

Humblet, Yves, et al.. (1990). Immunological and pharmacological removal of small cell lung cancer cells from bone marrow autografts. Lung Cancer. 6(1-2). 45–45. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact